Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camidanlumab tesirine in older patients with relapsed/refractory or PET-2-positive classical Hodgkin lymphoma
2020-004181-20Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camidanlumab tesirine in classical Hodgkin lymphoma (cHL), sponsored by European Institute of Oncology. Primary endpoint: Metabolic complete remission rate. Started Jul 2021; status: terminated.
02
Drugs
camidanlumab tesirine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2020-004181-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004181-20.